
A positive hepatitis C antibody result does not tell you whether the virus is still active, and feeling well does not rule out liver injury. You will learn which test confirms infection, how direct-acting antivirals clear HCV, what SVR12 means, and why liver condition and previous treatment affect the plan.
Key takeaways
- Direct-acting antivirals block HCV proteins needed for viral replication.
- An HCV RNA test confirms whether hepatitis C is actively infecting you.
- Treatment commonly lasts 8 or 12 weeks, depending on your clinical factors.
- Undetectable HCV RNA 12 weeks after treatment indicates a sustained virologic response.
How direct-acting antivirals clear hepatitis C
Direct-acting antivirals (DAAs) clear hepatitis C by stopping the virus from making copies of itself. They block essential HCV proteins, including the NS3/4A protease, NS5A protein, and NS5B polymerase. As replication stops, infected cells release less virus and the body eliminates the remaining infection. Modern regimens cure more than 95% of appropriately treated people.
Common DAA combinations include:
- Sofosbuvir/velpatasvir
- Glecaprevir/pibrentasvir
- Ledipasvir/sofosbuvir
A clinician selects the regimen according to the virus’s genotype or use of a pangenotypic regimen, cirrhosis or other liver damage, kidney function, previous treatment, and medicine interactions. Treatment commonly lasts 8 or 12 weeks, but advanced liver disease or prior treatment can change the plan.
Do not choose a combination from a past prescription; the wrong regimen can fail or interact with other medicines.
Treatment is considered a virologic cure when an HCV RNA blood test shows no detectable virus 12 weeks or more after the final dose. This result is called sustained virologic response, or SVR12.
An undetectable HCV RNA result during treatment shows suppression, not yet cure, and a positive antibody test can remain for life after clearance. Cure does not prevent reinfection through blood exposure, and no hepatitis C vaccine exists.
Which tests confirm active infection and prepare you for treatment
A positive anti-HCV antibody result shows that your immune system has encountered hepatitis C, but it does not prove that the virus remains. Antibodies usually stay positive for life after clearance. A quantitative HCV RNA test detects and measures virus in the blood, confirming active infection and providing a baseline for treatment.
An undetectable result means no HCV RNA is detected; recent exposure may require repeat testing.
| Test | What it tells you | Why it matters |
|---|---|---|
| anti-HCV antibody | Past or current exposure | Cannot distinguish cured infection from active infection |
| quantitative HCV RNA | Amount of virus currently in blood | Confirms infection and establishes a treatment baseline |
| HCV RNA after treatment | Whether virus remains after therapy | Undetectable RNA at least 12 weeks after completion confirms SVR12 |
Before prescribing direct-acting antivirals, clinicians commonly check:
- Liver function tests, including ALT, AST, bilirubin, albumin and alkaline phosphatase, to assess liver injury and function.
- A complete blood count (CBC) to identify anaemia, low platelets or other findings relevant to liver disease.
- Creatinine and estimated glomerular filtration rate (eGFR) to guide medicine selection and dosing.
- Cirrhosis or liver-cancer assessment, because advanced disease changes monitoring.
- Every prescription, over-the-counter medicine and supplement for drug interactions.
- Hepatitis B tests, because treatment can reactivate hepatitis B and require monitoring or preventive antiviral therapy.
A detectable HCV RNA early in treatment does not automatically mean failure. Do not stop without specialist advice; the decisive assessment is the post-treatment RNA test.
Why treatment lasts 8, 12, or more weeks
Eight weeks is enough for some people, while others need 12 weeks or longer. The decision depends on whether the infection is newly treated or previously unsuccessful, whether cirrhosis is present, the HCV genotype, kidney function, and the chosen DAA regimen.
Do not shorten treatment because symptoms or liver enzymes improve; the target is an undetectable HCV RNA result at least 12 weeks after the final dose, called SVR12.
A clinician matches duration and medicines to:
- HCV genotype, or whether a pangenotypic regimen covers it
- Cirrhosis, especially decompensated cirrhosis
- Previous DAA or interferon treatment and the reason it failed
- Kidney function and the safety profile of the selected drugs
- Drug interactions, including acid-reducing medicines, anticonvulsants, rifampin, some statins, transplant immunosuppressants, and St. John’s wort
- Hepatitis B status, because DAAs can trigger hepatitis B reactivation
Common combinations include:
- Sofosbuvir/velpatasvir
- Glecaprevir/pibrentasvir
- Ledipasvir/sofosbuvir
These combinations are not interchangeable. Glecaprevir/pibrentasvir is commonly used for an 8-week course in eligible people without cirrhosis, while other circumstances call for 12 weeks or an alternative plan. Prior treatment failure, resistant virus, advanced liver disease, or complex interactions can extend therapy or require specialist-selected medicines.
Take every dose for the prescribed duration, even if an HCV RNA test becomes undetectable during treatment.
What HCV RNA results mean during and after treatment
An undetectable HCV RNA result while you are taking direct-acting antivirals shows that the virus is suppressed at that moment, but it does not yet prove cure. A detectable result during treatment also does not by itself mean treatment has failed, so do not stop the prescribed course because of one early result.
The decisive check is HCV RNA at least 12 weeks after the final dose. If it is undetectable then, you have SVR12, the standard definition of virologic cure. If RNA remains detectable, persistent infection or relapse requires specialist reassessment and a treatment plan based on your previous regimen and liver condition.
After SVR12, follow-up depends on liver damage and the chance of new exposure:
- Without cirrhosis and without continuing exposure risk, you may need no routine HCV monitoring. Unexplained liver-test abnormalities still need medical review.
- With cirrhosis, continue liver care even after cure, including liver-cancer surveillance with ultrasound every six months and assessment for complications such as portal hypertension.
- With ongoing risk from infected blood, schedule periodic HCV RNA testing. Do not use an antibody test for this purpose: HCV antibodies usually remain positive for life, and a positive result cannot distinguish past clearance from HCV reinfection.
- If you have current or previous hepatitis B infection, follow the monitoring plan for hepatitis B reactivation during and after treatment.
When cirrhosis, kidney disease, cancer, or transplant changes the plan
Treatment changes when your liver reserve, kidney function, pregnancy status, cancer treatment, or transplant plans alter the safety balance. Review liver tests, kidney function, medicines, supplements, and hepatitis B status before choosing a regimen; hepatitis B reactivation during or after DAA therapy requires monitoring or preventive antiviral treatment.
- Compensated cirrhosis usually permits standard DAA treatment, but successful clearance does not remove liver-cancer risk. Continue liver ultrasound, with or without alpha-fetoprotein, about every six months indefinitely.
- Decompensated cirrhosis means ascites, variceal bleeding, jaundice, or hepatic encephalopathy. Manage it with an advanced-liver-disease or transplant team; avoid protease-inhibitor-containing regimens because they can be unsafe.
- Pregnancy changes the timing. Clinicians usually defer treatment until after delivery because pregnancy safety data are limited, and ribavirin must not be used during pregnancy or for six months before conception by either partner.
- Kidney disease affects drug selection and monitoring rather than automatically ruling out treatment. Check estimated glomerular filtration rate and kidney medicines; approved regimens now cover many people with advanced kidney disease.
- Liver cancer requires coordination with oncology because treatment timing can affect procedures, cancer therapy, and transplant assessment. Treating active cancer and hepatitis C is an individualized decision.
Before liver transplantation, curing HCV can prevent infection in the new liver but might improve liver function and change transplant priority. After liver transplantation, DAAs remain highly effective, with drug interactions and rejection medicines requiring close review. Dr Chetan Kalal Hepatologist Transplant can help coordinate hepatology and transplant follow-up.
Related services
HCV:- Hepatitis C Virus The hepatitis C virus is the source of the liver infection known as hepatitis C. (HCV). View service → |
Viral Hepatitis Care Clinic — Testing, Treatment & Prevention Dr. Chetan Kalal’s Hepatitis B & C Clinic in Mumbai offers expert consultation, diagnosis, and comprehensive treatment for patients suffering from... View service → |
Frequently asked questions
How do direct-acting antivirals clear hepatitis C?
They block essential HCV proteins, including NS3/4A protease, NS5A, and NS5B polymerase, stopping the virus from making copies. The body then clears the remaining infection.
Which tests confirm active hepatitis C infection?
An HCV antibody test shows whether you have been exposed. A detectable HCV RNA test confirms current infection. Clinicians also assess liver fibrosis, kidney function, hepatitis B status, and drug interactions before treatment.
Why does hepatitis C treatment last 8, 12, or more weeks?
Duration depends on the antiviral regimen, HCV genotype, previous treatment, cirrhosis, viral factors, and other health conditions. Difficult-to-treat cases can require longer treatment.
What does an HCV RNA result mean after treatment?
A detectable result during treatment means viral RNA remains measurable and requires clinical review. An undetectable result 12 weeks after treatment is called sustained virologic response and indicates a cure in most patients.
When do cirrhosis, kidney disease, cancer, or transplant change the treatment plan?
These conditions affect regimen selection, monitoring, timing, and drug interactions. Advanced cirrhosis, kidney disease, liver cancer, or transplant history requires specialist planning rather than self-directed treatment.






